BCO Podcast: Evolving Mutations in Metastatic Breast Cancer

Moderators

Evolving Mutations in Metastatic Breast Cancer

April 16, 2018

Dr. Utthara Nayar is a research fellow in medicine at the Dana-Farber Cancer Institute, the Harvard medical School, and the Broad Institute of MIT and Harvard. A cancer biologist, her broad research focuses on the interface of basic biology, targeted medicines, and drug resistance. At the 2018 American Association for Cancer Research Annual Meeting, she's presented research looking at how acquired HER2 mutations can make some metastatic hormone-receptor-positive breast cancers resistant to hormonal therapy.

Listen to the podcast to hear Dr. Nayar explain:

• the number of metastatic hormone-receptor-positive breast cancers that become resistant to hormonal therapy
• what whole-exome sequencing is and why she and her colleagues used it in this study
• the possibility that genetic sequencing of cancers could be an ongoing part of treatment at some point in the future

Running time: 15:08

Listen now or read the transcript

.

Grannax2

Mods what is the name of the other drug they used with faslodex. It sounds like shes saying neurolinks but I don't think im spelling it correctly.

ABeautifulSunset

grannax, it’s neratinib (or nerlynx, I believe).

Grannax2

This is a really interesting podcast, especially for those of us interested in genomic testing results and how they can be used in TX. My results show that my tumors are now resistant to all aromitace inhibitors. This Dr says that 25% of MBC are. She also talks about how HER 2- can change and respond more like HER+. She says MO should look at not only pathology but genomic alterations to decide TX.

In a small study they used nerlynx and faslodex and got encouraging results.💞

Moderators

Sorry we're just seeing this Grannax2! ABeautifulSunset is correct -- the drug is Nerlynx. You can read more on this drug on the main Breastcancer.org site's Nerlynx pages.

We hope this helps!

--The Mods